Browsing Haematology (Scholarly Publications) by Author "Browne, Paul"
Now showing items 1-4 of 4
- Sort by:
- title
- issue date
- submit date
- Order:
- ascending
- descending
- Results:
- 5
- 10
- 20
- 40
- 60
- 80
- 100
-
The Impact of Advanced Patient Age on Mortality after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma: A Retrospective Study by the European Society for Blood and Marrow Transplantation Lymphoma Working Party
Browne, Paul; Kyriakou, Charalampia; Boumendil, Ariane; Finel, Herve; Schmitz, NN Norbert; Smedegaard Andersen, Niels; Blaise, Didier; Chevallier, Patrice; Browne, Paul; Malladi, Ram; Niederwieser, Dietger; Pagliuca, Antonio; Kroschinsky, Frank; Montoto, Silvia; Dreger, Peter; EBMT Lymphoma Working Party (2019)More than 60% of patients with non-Hodgkin lymphoma (NHL) are age>60 years at presentation. The purpose of thisstudy was to compare the potential risks and benefits of allogeneic hematopoietic cell transplantation (alloHCT) ... -
Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents
Browne, Paul; Sahebi, Firoozeh; Iacobelli, Simona; Sbianchi, Giulia; Koster, Linda; Blaise, Didier; Reményi, Péter; Russell, Nigel H.; Ljungman, Per; Kobbe, Guido; Apperley, Jane; Trneny, Marek; Krejci, Marta; Wiktor-Jedrzejczak, Wieslaw; Sanchez, James F.; Schaap, Nicolaas; Isaakson, Cecilia; Lenhoff, Stig; Scheid, Christof; Wilson, Keith M.O.; Yakoub-Agha, Ibrahim; González Muñiz, Soledad; Schönland, Stefan; Morris, Curly; Garderet, Laurent; Kröger, Nicolaus (2018)The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPMs). We examined the SPM rate in MM patients who were enrolled in the prospective ... -
Melphalan 140 mg/m2or 200 mg/m2for autologous transplantation in myeloma: Results from the collaboration to collect autologous transplant outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT chronic malignancies working party
Browne, Paul; Auner, Holger W.; Iacobelli, Simona; Sbianchi, Giulia; Knol-Bout, Cora; Blaise, Didier; Russell, Nigel H.; Apperley, Jane F.; Pohlreich, David; Kobbe, Guido; Isaksson, Cecilia; Lenhoff, Stig; Scheid, Christof; Touzeau, Cyrille; Jantunen, Esa; Anagnostopoulos, Achilles; Yakoub-Agha, Ibrahim; Tanase, Alina; Schaap, Nicolaas; Wiktor-Jedrzejczak, Wieslaw; Krejci, Marta; Schönland, Stefan O.; Morris, Curly; Garderet, Laurent; Kröger, Nicolaus (2018)Melphalan at a dose of 200 mg/m2 is standard conditioning prior to autologous hematopoietic stem cell transplantation for multiple myeloma, but a dose of 140 mg/m2 is often used in clinical practice in patients perceived ... -
A novel aryl-guanidinium derivative, VP79s, targets the signal transducer and activator of transcription 3 signaling pathway, downregulates myeloid cell leukaemia-1 and exhibits preclinical activity against multiple myeloma
Mc Elligott, Tony; Rozas, Isabel; Zisterer, Daniela; Hayden, Patrick; Lynam-Lennon, Niamh; Browne, Paul (2022)Aims: We have recently described a novel guanidinium-based compound, VP79s, which induces cytotoxicity in various cancer cell lines. Here, we aim to investigate the activity of VP79s and associated mechanisms of action in ...